三七多糖对糖尿病模型大鼠的降血糖作用和眼视网膜病变的治疗作用及其机制

发布时间：2018-08-04 13:32

【摘要】：目的:通过注射链脲佐菌素(STZ)制备大鼠糖尿病眼病模型,探讨三七多糖对糖尿病模型大鼠的降血糖作用及其眼病的治疗作用,阐明其作用机制。方法:70只SD雄性大鼠分为对照组(10只)和造模组(60只),造模组大鼠给予高脂饲料喂养。2周后,造模组大鼠腹腔注射35mg·kg~(-1)STZ制备高血糖模型。3d后,动物禁食不禁水12h,检测空腹血糖(FBG)水平,以FBG11.1mmol·L-1为造模成功标准。选取造模成功的大鼠,随机分为模型组,二甲双胍(150 mg·kg~(-1))组,低、中、高剂量(75、150和300 mg·kg~(-1))三七多糖组。灌胃给药5和8周后检测大鼠FBG水平,8周后检测大鼠糖耐量,处死大鼠取肝脏检测肝糖原水平,检测血清谷胱甘肽(GSH)和一氧化氮(NO)水平。分离大鼠视网膜,Q-PCR法检测血管内皮生长因子(VEGF)及诱导型一氧化氮合酶(iNOS)的表达水平,HE染色观察其组织形态表现。结果:与模型组比较,用药5周后,中剂量三七多糖组大鼠FBG水平明显降低(P0.05);用药8周后,不同剂量三七多糖组大鼠FBG、糖耐量和肝糖原水平明显降低(P0.05或P0.01)。血清检测,与模型组比较,高剂量三七多糖组大鼠GSH水平明显升高,NO水平明显降低(P0.05或P0.01)。Q-PCR法检测,与模型组比较,高剂量三七多糖组大鼠视网膜中VEGF和iNOS表达水平明显降低(P0.05)。HE染色,与模型组比较,中和低剂量三七多糖组大鼠视网膜部分血管增生,未见视网膜萎缩;高剂量三七多糖组大鼠视网膜血管增生状态明显改善,未见视网膜萎缩。结论:三七多糖具有降血糖的作用,同时可以通过升高GSH和NO水平、提高VEGF和iNOS基因表达水平,起到治疗糖尿病引起的视网膜病变的作用。
[Abstract]:Aim: to investigate the hypoglycemic effect of Panax notoginseng polysaccharide (PNS) on diabetic rats and the therapeutic effect of streptozotocin (STZ) on diabetic ophthalmopathy in rats, and to elucidate its mechanism. Methods 70 Sprague-Dawley male rats were divided into two groups: control group (n = 10) and model group (n = 60). Rats in the model group were fed with high-fat diet for .2 weeks, and rats in the model group were given intraperitoneal injection of 35mg kg-1 STZ to make hyperglycemic model for 3 days. Fasting for 12 h, fasting blood glucose (FBG) level was measured. FBG11.1mmol L-1 was used as the successful standard for modeling. The rats were randomly divided into two groups: model group, metformin (150mg kg-1) group, low, medium and high dose (75150 and 300mg kg-1) panax notoginseng polysaccharide group. After 5 and 8 weeks of intragastric administration, the levels of FBG in rats were measured. After 8 weeks of administration, the glucose tolerance of rats was measured. The liver of the rats was sacrificed to detect the levels of liver glycogen, and the levels of serum glutathione (GSH) and nitric oxide (NO) were detected. The expression of vascular endothelial growth factor (VEGF) and inducible nitric oxide synthase (iNOS) were detected by Q-PCR in isolated rat retina. Results: compared with the model group, the level of FBG, glucose tolerance and liver glycogen in the middle dose panax notoginseng polysaccharide group decreased significantly after 5 weeks (P0.05), and after 8 weeks, the glucose tolerance and liver glycogen level decreased significantly (P0.05 or P0.01). Compared with the model group, the serum level of GSH in the high dose panax notoginseng polysaccharide group was significantly increased and decreased (P0.05 or P0.01) .Q-PCR, and compared with the model group. The expression of VEGF and iNOS in the retina of high dose panax notoginseng polysaccharide group was significantly decreased (P0.05) .HE staining, compared with the model group, moderate and low doses of panax notoginseng polysaccharide group rats retinal vascular hyperplasia, no retinal atrophy; The retinal vascular hyperplasia of rats in high dose panax notoginseng polysaccharide group was obviously improved, and no retinal atrophy was found. Conclusion: Panax notoginseng polysaccharides can decrease blood glucose and increase the expression of VEGF and iNOS genes by increasing the levels of GSH and no, and can play a role in the treatment of diabetic retinopathy.
【作者单位】：承德医学院附属医院眼科;
【基金】：河北省科技厅自然科学基金资助课题(H2015406054)
【分类号】：R285.5;R-332

【相似文献】